Type C TP53-CDKN1A pathway dysfunction occurs independently of CDKN1A gene polymorphisms in chronic lymphocytic leukaemia and is associated with TP53 abnormalities.
Department of Molecular Pathology, Royal Bournemouth Hospital, Bournemouth, Dorset, UK.
Ian
I
Tracy
Genetic Epidemiology and Bioinformatics Research Group, Faculty of Medicine, University of Southampton, Southampton, UK.
William
W
Tapper
Department of Molecular Pathology, Royal Bournemouth Hospital, Bournemouth, Dorset, UK.
Anton
A
Parker
Department of Molecular Pathology, Royal Bournemouth Hospital, Bournemouth, Dorset, UK.
Anne
A
Gardiner
Department of Haematology, James Paget University Hospitals, Great Yarmouth, UK.
Shalal
S
Sadullah
Department of Haematology, Birmingham Heartlands Hospital, Birmingham, UK.
Guy
G
Pratt
Department of Haematology, Derriford Hospital, Plymouth, UK.
Adrian
A
Copplestone
Department of Molecular Pathology, Royal Bournemouth Hospital, Bournemouth, Dorset, UK.
David
D
Oscier
Department of Molecular Pathology, Royal Bournemouth Hospital, Bournemouth, Dorset, UK.
Oliver Giles
OG
Best
D000483:Alleles; D050759:Cyclin-Dependent Kinase Inhibitor p21 / Q000235:genetics* / Q000378:metabolism*; D004249:DNA Damage; D015870:Gene Expression; D005838:Genotype; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy / Q000235:genetics* / Q000378:metabolism*; D011110:Polymorphism, Genetic; D020641:Polymorphism, Single Nucleotide; D015398:Signal Transduction; D016159:Tumor Suppressor Protein p53 / Q000235:genetics* / Q000378:metabolism*
C493956:CDKN1A protein, human; D050759:Cyclin-Dependent Kinase Inhibitor p21; D016159:Tumor Suppressor Protein p53

TP53
; cell signalling; chronic lymphocytic leukaemia